Alnylam Pharmaceuticals Inc (0HD2)
LSE
Closed
Aug 21, 2026
Day's Range
226.0052 wk Range
199.81Overview - 0HD2 - Alnylam Pharmaceuticals Inc
Key Statistics
Valuation
Enterprise Value
31.35B
P/E (Trailing)
‪8.26‬
Price / Sales (TTM)
‪0.0041‬
Price / Book
‪23.37‬
EV / EBITDA
‪29.73‬
Profitability
Gross Margin
‪54.26%‬
Profit Margin
‪16.12%‬
Operating Margin
‪17.92%‬
Return on Assets
‪12.34%‬
Return on Equity
‪96.55%‬
Ownership
Shares Outstanding
101.03M
Float
133.23M
Held by Insiders
‪0.18%‬
Held by Institutions
‪101.71%‬
Price stats
Beta
‪0.27‬
50-Day Avg
‪170.73‬
200-Day Avg
‪180.79‬
Market Cap - 0HD2 - Alnylam Pharmaceuticals Inc
Peers - 0HD2 - Alnylam Pharmaceuticals Inc
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0HD2LSEAlnylam Pharmaceuticals Inc23.91BMarket Cap-88.62%52-week change8.26P/E (Trailing)‪16.12%‬Profit Margin
- 0MGBLSEGenmab A/S173.69BMarket Cap+27.59%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.34BMarket Cap+29.12%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+31.55%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.72.10BMarket Cap+82.56%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.61BMarket Cap+34.75%52-week change42.42P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.47%52-week change128.71P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0HD2 - Alnylam Pharmaceuticals Inc
About
Alnylam Pharmaceuticals Inc is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of therapeutics based on RNA interference technology. The company focuses on treating genetically defined and other hard-to-treat diseases by silencing specific genes…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
